Trial Profile

A Phase II Trial Comparing Efficacy and Safety of GZR101 and Insulin Degludec/Insulin Aspart in Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drug (OAD) Therapy or OAD Therapy in Combination With Insulin

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin aspart biosimilar/long acting insulin fixed dose combination Gan and Lee Pharmaceuticals (Primary) ; Insulin aspart; Insulin degludec
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Gan&Lee Pharmaceuticals

19 Dec 2023 New trial record
11 Dec 2023 According to Gan & Lee Pharmaceuticals media release, the company announced the initiation and completion of the first patient dosing in the Phase II clinical study of its Class 1 Innovative drug, GZR101 injection; The study plans to enroll 150 patients across 25 clincial sites nationwide.
11 Dec 2023 Status changed from not yet recruiting to recruiting as per Gan & Lee Pharmaceuticals media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com